Kovack Advisors Inc. Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kovack Advisors Inc. lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 347.1% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 29,971 shares of the specialty pharmaceutical company’s stock after acquiring an additional 23,267 shares during the period. Kovack Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $3,686,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Daiwa Securities Group Inc. boosted its position in Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after buying an additional 100 shares during the last quarter. Waterfront Wealth Inc. boosted its position in Jazz Pharmaceuticals by 1.2% in the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company’s stock valued at $1,062,000 after buying an additional 103 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its position in Jazz Pharmaceuticals by 4.3% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after buying an additional 108 shares during the last quarter. Johnson Investment Counsel Inc. boosted its position in Jazz Pharmaceuticals by 0.8% in the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock valued at $1,695,000 after buying an additional 110 shares during the last quarter. Finally, Fifth Third Bancorp boosted its position in Jazz Pharmaceuticals by 2.2% in the third quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company’s stock valued at $691,000 after buying an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded up $2.03 during trading hours on Friday, hitting $109.46. 480,574 shares of the company’s stock were exchanged, compared to its average volume of 604,480. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The firm has a market cap of $6.90 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.50 and a beta of 0.59. The firm has a 50 day moving average of $118.25 and a two-hundred day moving average of $121.81. Jazz Pharmaceuticals plc has a fifty-two week low of $106.61 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JAZZ. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 30th. Royal Bank of Canada reissued an “outperform” rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, February 29th. Stifel Nicolaus boosted their price target on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a report on Friday, March 15th. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Finally, Barclays decreased their price target on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, March 1st. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $195.08.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The stock was bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.